Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pasireotide
Drug ID BADD_D01684
Description Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Indications and Usage For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Marketing Status approved
ATC Code H01CB05
DrugBank ID DB06663
KEGG ID D10147
MeSH ID C517782
PubChem ID 9941444
TTD Drug ID D0TV0C
NDC Product Code 71161-128; 71161-129; 55292-133; 55292-142; 55292-143; 55292-139; 55292-141; 71161-130; 71161-127; 71161-126; 55292-140; 55292-131; 55292-132
UNII 98H1T17066
Synonyms pasireotide | cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-d-tryptophyl-L-lysyl-4-o-benzyl-L-tyrosyl-L-phenylalanyl-) | SOM-230 | SOM 230 | SOM230
Chemical Information
Molecular Formula C58H66N10O9
CAS Registry Number 396091-73-9
SMILES C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4 )OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypothyroidism14.11.01.012; 05.02.03.001--
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site pruritus08.02.03.013; 23.03.12.007; 12.07.03.0140.000633%Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.0110.000186%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Ketoacidosis14.01.01.0080.000279%Not Available
Lipase increased13.05.01.003--
Malaise08.01.01.0030.000876%
Mitral valve incompetence02.07.01.0020.000186%Not Available
Myalgia15.05.02.0010.000279%
Myocardial infarction24.04.04.009; 02.02.02.0070.000373%
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.004993%
Nephrolithiasis20.04.01.0020.000186%
Neuralgia17.02.07.0050.000633%
Oedema14.05.06.010; 08.01.07.0060.000186%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000279%
Osteoporosis15.02.03.002; 14.04.04.0020.000186%
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.0120.000596%
Pancreatitis07.18.01.0010.000373%
Pancreatitis acute07.18.01.002--Not Available
Phlebitis24.12.03.004; 12.02.01.0020.000186%
Pituitary-dependent Cushing's syndrome24.08.04.009; 14.11.01.055; 05.03.01.004--Not Available
Pollakiuria20.02.02.0070.000410%
Polydipsia14.05.02.001; 05.03.03.0020.000373%Not Available
Polyuria20.02.03.0020.000652%Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages